Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer

作者：Di Lauro Luigi^*; Vici Patrizia; Belli Franca; Tomao Silverio; Fattoruso Silvia Ileana; Arena Maria Grazia; Pizzuti Laura; Giannarelli Diana; Paoletti Giancarlo; Barba Maddalena; Sergi Domenico; Maugeri Sacca Marcello

来源：Gastric Cancer, 2014, 17(4): 718-724.

DOI：10.1007/s10120-013-0321-3

• Gastric cancer
• Docetaxel
• Oxaliplatin
• Capecitabine
• Phase II

The incorporation of docetaxel into the cisplatin and fluorouracil backbone has been demonstrated to be an active combination in metastatic gastric cancer. Nevertheless, this regimen is burdened by nonnegligible toxicity. We hypothesized that replacing cisplatin and fluorouracil with oxaliplatin and capecitabine should be an active and safe option for metastatic gastric cancer patients.
In this phase II study, we tested the activity of docetaxel in combination with oxaliplatin and capecitabine (DOC) as a first-line treatment. DOC was administered as follows: docetaxel (60 mg/m(2)) and oxaliplatin (100 mg/m(2)) on day 1, and capecitabine (500 mg/m(2)) was administered orally twice daily given continuously, with cycles repeated every 3 weeks. The primary endpoint was the overall response rate.
Forty-eight patients entered the study. All patients had metastatic disease (stage IV). None of the patients had previously received chemotherapy for advanced disease. Performance status was 0, 1, and 2 in 25, 58, and 17 % of patients, respectively; 13 patients (27 %) had adenocarcinoma of the gastroesophageal junction, and 29 patients (60.5 %) had two or more metastatic sites. The overall response rate was 52.1 %. Progression-free survival and overall survival were 6.9 and 12.6 months, respectively. The treatment was well tolerated with no treatment-related deaths. The most common grade 3-4 toxicity was neutropenia (41 %).
DOC is an effective and tolerated first-line treatment, and the lower dose of docetaxel and oxaliplatin used in this study compared with other similar regimens does not seem to hamper the antitumor activity.

• 出版日期2014-10